Long-Term Assessment of Lurasidone in Schizophrenia: Post Hoc Analysis of a 12-Month, Double Blind, Active-Controlled Trial and 6-Month Open-Label Extension Study.

Patel, Preeya J; Weidenfeller, Christian; Jones, Andrew P; Nilsson, Jens; Hsu, Jay

Patel, Preeya J; Weidenfeller, Christian; Jones, Andrew P; Nilsson, Jens; Hsu, Jay.

Afiliação

Patel PJ; Sunovion Pharmaceuticals Europe Ltd, London, UK. Preeya.Patel@sunovion.com.
Weidenfeller C; Sunovion Pharmaceuticals Europe Ltd, London, UK.
Jones AP; Sunovion Pharmaceuticals Europe Ltd, London, UK.
Nilsson J; Sunovion Pharmaceuticals Europe Ltd, London, UK.
Hsu J; Sunovion Pharmaceuticals Inc., Fort Lee, NJ, USA.

Neurol Ther ; 10(1): 121-147, 2021 Jun.

Article em En | MEDLINE | ID: mdl-33098548

Palavras-chave

Atypical antipsychotic; Cardiometabolic; Lurasidone; Metabolic syndrome; Prolactin; Risperidone; Schizophrenia; Switch

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Idioma: En Revista: Neurol Ther Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google